Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank79
3Y CAGR-6.1%
5Y CAGR-4.9%
Year-over-Year Change
EBITDA as a percentage of revenue
3Y CAGR
-6.1%/yr
vs +21.0%/yr prior
5Y CAGR
-4.9%/yr
Consistent
Acceleration
-27.1pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 41.14% | +832.4% |
| 2024 | 4.41% | -90.5% |
| 2023 | 46.66% | -6.0% |
| 2022 | 49.67% | +28.9% |
| 2021 | 38.52% | -27.2% |
| 2020 | 52.93% | +41.2% |
| 2019 | 37.48% | +61.6% |
| 2018 | 23.19% | +458.9% |
| 2017 | 4.15% | -6.4% |
| 2016 | 4.43% | - |